PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI) a biotechnology company traded on the Tel-Aviv Stock Exchange. The Company’s pre-clinical studies show that CF102 is also active against Hepatitis B virus, in addition to liver cancer, which is the first indication being developed. The new discovery opens up for Can-Fite a potentially significant target market of approximately 3 billion dollars, and may lead to the accelerated development of CF102, which Can-Fite is developing alongside its first drug, CF101, which is already in various phases of clinical trials in the United States, Europe and Israel.
